Please Wait.....
Report
NA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 194 Pages I Data Bridge Market Research
North America breast cancer diagnostics market is projected to register a CAGR of 9.5% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.
Market Segmentation:
North America Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the North America breast cancer diagnostics market are:
- Increasing breast cancer patients among the women population as well as men
- Rise in technological advancement for breast cancer diagnostic
Market Players
The key market players operating in the North America breast cancer diagnostics market are:
- F-Hoffmann La Roche Ltd.
- Siemens Healthcare GmbH
- General Electric
- Koninklijke Philips N.V.
- FUJIFILM Corporation
- Abbott
- Hologic, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 48
1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE NORTH AMERICA BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50
2 MARKET SEGMENTATION 54
2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 69
4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71
5 EPIDEMIOLOGY 72
6 INDUSTRIAL INSIGHTS 73
7 REGULATORY FRAMEWORK 74
8 MARKET OVERVIEW 76
8.1 DRIVERS 78
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83
9 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84
9.1 OVERVIEW 85
9.2 IMAGING 88
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
9.2.1.2 ANALOG MAMMOGRAPHY 90
9.2.1.3 3D BREAST TOMOSYNTHESIS 90
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
9.2.1.7 OTHERS 90
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
9.2.2.1 OPTICAL IMAGING 91
9.2.2.2 BREAST ULTRASOUND 91
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
9.2.2.5 BREAST THERMOGRAPHY 92
9.2.3 BIOPSY 92
9.2.3.1 SURGICAL BIOPSY 93
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
9.2.3.3 CORE NEEDLE BIOPSY 93
9.2.3.4 IMAGE-GUIDED BIOPSY 93
9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
9.2.4 GENOMIC TEST 94
9.2.4.1 MOLECULAR TESTING 95
9.2.4.1.1 PD-L1 96
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
9.2.4.1.3 NTRK GENE FUSIONS 96
9.2.4.1.4 PI3KCA GENE MUTATION 96
9.2.4.2 MAMMAPRINT 96
9.2.4.3 ONCOTYPE DX 96
9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98
10 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99
10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105
11 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106
11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112
12 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114
12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119
13 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120
13.1 NORTH AMERICA 121
13.1.1 U.S. 129
13.1.2 CANADA 135
13.1.3 MEXICO 141
14 NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 147
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 147
15 SWOT ANALYSIS 148
16 COMPANY PROFILE 149
16.1 HOLOGIC, INC. 149
16.1.1 COMPANY SNAPSHOT 149
16.1.2 REVENUE ANALYSIS 149
16.1.3 COMPANY SHARE ANALYSIS 150
16.1.4 PRODUCT PORTFOLIO 150
16.1.5 RECENT DEVELOPMENTS 151
16.2 SIEMENS HEALTHCARE GMBH 152
16.2.1 COMPANY SNAPSHOT 152
16.2.2 REVENUE ANALYSIS 153
16.2.3 COMPANY SHARE ANALYSIS 153
16.2.4 PRODUCT PORTFOLIO 154
16.2.5 RECENT DEVELOPMENTS 154
16.3 F. HOFFMANN- LA ROCHE LTD 155
16.3.1 COMPANY SNAPSHOT 155
16.3.2 REVENUE ANALYSIS 155
16.3.3 COMPANY SHARE ANALYSIS 156
16.3.4 PRODUCT PORTFOLIO 156
16.3.5 RECENT DEVELOPMENTS 157
16.4 KONINKLIJKE PHILIPS N.V. 158
16.4.1 COMPANY SNAPSHOT 158
16.4.2 REVENUE ANALYSIS 158
16.4.3 COMPANY SHARE ANALYSIS 159
16.4.4 PRODUCT PORTFOLIO 159
16.4.5 RECENT DEVELOPMENTS 160
16.5 ABBOTT 161
16.5.1 COMPANY SNAPSHOT 161
16.5.2 REVENUE ANALYSIS 161
16.5.3 COMPANY SHARE ANALYSIS 162
16.5.4 PRODUCT PORTFOLIO 162
16.5.5 RECENT DEVELOPMENTS 162
16.6 ABACUS ALS 163
16.6.1 COMPANY SNAPSHOT 163
16.6.2 PRODUCT PORTFOLIO 163
16.6.3 RECENT DEVELOPMENTS 163
16.7 BD 164
16.7.1 COMPANY SNAPSHOT 164
16.7.2 REVENUE ANALYSIS 164
16.7.3 COMPANY SHARE ANALYSIS 165
16.7.4 PRODUCT PORTFOLIO 165
16.7.5 RECENT DEVELOPMENTS 165
16.8 BIOCEPT, INC. 166
16.8.1 COMPANY SNAPSHOT 166
16.8.2 REVENUE ANALYSIS 166
16.8.3 PRODUCT PORTFOLIO 167
16.8.4 RECENT DEVELOPMENTS 167
16.9 BIOMERIEUX 168
16.9.1 COMPANY SNAPSHOT 168
16.9.2 REVENUE ANALYSIS 168
16.9.3 PRODUCT PORTFOLIO 169
16.9.4 RECENT DEVELOPMENTS 169
16.10 BIO-RAD LABORATORIES, INC. 170
16.10.1 COMPANY SNAPSHOT 170
16.10.2 REVENUE ANALYSIS 170
16.10.3 PRODUCT PORTFOLIO 171
16.10.4 RECENT DEVELOPMENT 171
16.11 CEPHEID 172
16.11.1 COMPANY SNAPSHOT 172
16.11.2 REVENUE ANALYSIS 172
16.11.3 PRODUCT PORTFOLIO 173
16.11.4 RECENT DEVELOPMENT 173
16.12 EXACT SCIENCES CORPORATION 174
16.12.1 COMPANY SNAPSHOT 174
16.12.2 REVENUE ANALYSIS 174
16.12.3 COMPANY SHARE ANALYSIS 175
16.12.4 PRODUCT PORTFOLIO 175
16.12.5 RECENT DEVELOPMENTS 176
16.13 FUJIFILM CORPORATION 177
16.13.1 COMPANY SNAPSHOT 177
16.13.2 REVENUE ANALYSIS 177
16.13.3 PRODUCT PORTFOLIO 178
16.13.4 RECENT DEVELOPMENT 178
16.14 GENERAL ELECTRIC 179
16.14.1 COMPANY SNAPSHOT 179
16.14.2 REVENUE ANALYSIS 179
16.14.3 PRODUCT PORTFOLIO 180
16.14.4 RECENT DEVELOPMENTS 180
16.15 ILLUMINA, INC. 181
16.15.1 COMPANY SNAPSHOT 181
16.15.2 REVENUE ANALYSIS 181
16.15.3 PRODUCT PORTFOLIO 182
16.15.4 RECENT DEVELOPMENTS 182
16.16 MYRIAD GENETICS, INC. 183
16.16.1 COMPANY SNAPSHOT 183
16.16.2 REVENUE ANALYSIS 183
16.16.3 PRODUCT PORTFOLIO 184
16.16.4 RECENT DEVELOPMENT 184
16.17 NANOSTRING. 185
16.17.1 COMPANY SNAPSHOT 185
16.17.2 REVENUE ANALYSIS 185
16.17.3 PRODUCT PORTFOLIO 186
16.17.4 RECENT DEVELOPMENT 186
16.17.5 RECENT DEVELOPMENT 186
16.18 ONCOSTEM. 187
16.18.1 COMPANY SNAPSHOT 187
16.18.2 PRODUCT PORTFOLIO 187
16.18.3 RECENT DEVELOPMENT 187
16.19 PROVISTA DIAGNOSTICS. 188
16.19.1 COMPANY SNAPSHOT 188
16.19.2 PRODUCT PORTFOLIO 188
16.19.3 RECENT DEVELOPMENT 188
16.20 THERMO FISHER SCIENTIFIC INC. 189
16.20.1 COMPANY SNAPSHOT 189
16.20.2 REVENUE ANALYSIS 189
16.20.3 PRODUCT PORTFOLIO 190
16.20.4 RECENT DEVELOPMENT 190
17 QUESTIONNAIRE 191
18 RELATED REPORTS 194
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security